These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34712230)

  • 21. Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
    Smithy JW; Pianko MJ; Maher C; Postow MA; Shoushtari AN; Momtaz P; Chapman PB; Wolchok JD; Park JH; Callahan MK
    J Immunother; 2021 Jan; 44(1):9-15. PubMed ID: 33290361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
    J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD14
    Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
    Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
    Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
    J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
    Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
    Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
    Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
    Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
    Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
    Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood.
    Rad Pour S; Pico de Coaña Y; Demorentin XM; Melief J; Thimma M; Wolodarski M; Gomez-Cabrero D; Hansson J; Kiessling R; Tegner J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
    Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
    Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
    [No Abstract]   [Full Text] [Related]  

  • 31. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.
    Youn JI; Park SM; Park S; Kim G; Lee HJ; Son J; Hong MH; Ghaderpour A; Baik B; Islam J; Choi JW; Lee EY; Kim HR; Seo SU; Paik S; Yoon HI; Jung I; Xin CF; Jin HT; Cho BC; Seong SY; Ha SJ; Kim HR
    Sci Rep; 2020 Jun; 10(1):9050. PubMed ID: 32493990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy.
    Pal S; Nandi M; Dey D; Chakraborty BC; Shil A; Ghosh S; Banerjee S; Santra A; Ahammed SKM; Chowdhury A; Datta S
    Aliment Pharmacol Ther; 2019 May; 49(10):1346-1359. PubMed ID: 30982998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
    Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
    Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
    Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
    Joshi K; Atwal D; Ravilla R; Pandey Y; Yarlagadda N; Kakadia S; Makhoul I; Hutchins L; Mahmoud F
    Perm J; 2020; 24():. PubMed ID: 32097116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
    Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
    Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
    Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
    Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.
    Tietze JK; Angelova D; Heppt MV; Ruzicka T; Berking C
    Exp Dermatol; 2017 Jul; 26(7):622-629. PubMed ID: 27892653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.